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Background Celiac disease (CD) diagnosis is becoming
more difficult as patients with no intestinal histology
lesions may also be suffering from CD.
Aim To evaluate the diagnostic accuracy of
antiendomysium (EmA) assay in the culture medium of
intestinal biopsies for CD diagnosis.
Patients and methods The clinical charts of 418 patients
with CD and 705 non-CD controls who had all undergone
EmA assay in the culture medium were reviewed.
Results EmA assay in the culture medium had a higher
sensitivity (98 vs. 80%) and specificity (99 vs. 95%)
than serum EmA/antibodies to tissue transglutaminase
(anti-tTG) assay. All patients with CD who were tested
as false-negatives for serum EmA and/or anti-tTG
(32 adults and 39 children) carried the human
leukocyte antigen alleles associated to CD. Furthermore,
during the follow-up, four patients with negative-serum
EmA/anti-tTG, normal villi architecture, and positive-EmAs
in the culture medium, developed villous atrophy and
underwent gluten-free diet with consequent resolution
of the symptoms and complete intestinal histology
recovery.
Conclusion EmA assay in the culture medium should be
included in the diagnostic criteria for CD diagnosis in
‘seronegative’ patients. Eur J Gastroenterol Hepatol
00:000–000 !c 2011 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Celiac disease (CD) diagnosis is still anchored to the
criteria established by the European Society of Pediatric
Gastroenterology Hepatology and Nutrition in 1990 [1].
These require the mandatory presence of (a) villous
atrophy with crypt hyperplasia and increased intraepithe-
lial lymphocytes (IEL) count when the patient is eating
gluten and (b) a full clinical remission after elimination of
gluten from the diet. However, 20 years after those
diagnostic criteria were established, there is now growing
evidence that at least two other factors must be considered.
First, symptomatic gluten sensitivity and malabsorption
may coexist with a normal-looking mucosa [2–4]. Second,
the finding of circulating IgA antibodies to tissue
transglutaminase (anti-tTG) or endomysium (EmA) at
diagnosis is an extremely accurate diagnostic instru-
ment [5,6]. As a consequence, in many gastroenterology
centers CD diagnosis is nowadays also being done in
symptomatic patients presenting with a normal-looking
mucosa but with a high titer of serum anti-tTg or EmA
antibodies [7]. However, patients with minimal or no
intestinal histology lesions pose a considerable problem,
as serum anti-tTG and EmA are known to be often
negative in patients with CD with mild intestinal
damage [8,9].
In this study, we retrospectively reviewed our 12-year
experience of using EmA assay in the culture medium of
duodenal biopsies in patients with suspected CD,
expanded our previous data [9] and showed the clinical
characteristics of some patients with CD who, at the first
observation, were positive for EmA assay in the culture
medium but did not fulfill the CD diagnostic criteria and
successively developed intestinal villi atrophy.
Patients and methods
The study included patients referred between May 1997
and December 2007 to two centers in Palermo: adults at
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the Internal Medicine Department of the University
Hospital and children at the Pediatric Gastroenterology
Department of the Di Cristina Hospital. We reviewed the
clinical records of all patients who, during the previous 10
years, had undergone in-vitro study for EmA production
in cultured duodenal mucosa samples for suspected CD.
Inclusion criteria comprised one or more of the following
symptoms: weight loss, anemia, chronic diarrhea or con-
stipation, abdominal pain, dyspepsia, alternating bowel
habits, cryptogenetic hypertransaminasemia, recurrent
aphtosis, dental enamel defects, thyroiditis, joints pain,
and dermatitis. Patients with a family history of CD were
included in this study only if they showed one or more of
the above symptoms. Patients with IgA deficiency were
excluded from the study.
In all the patients, CD diagnosis was made according to
the following criteria: (a) in symptomatic patients with
positive-serum EmA and/or anti-tTG and evidence of
intestinal histology damage (grade 1–3 [10]) at first
evaluation on the basis of the disappearance of both
symptoms and serum antibody positivity on a gluten-free
diet (GFD); (b) in symptomatic patients with negative-
serum antibodies (EmA and anti-tTG) and evidence of
intestinal histology damage on the basis of the disap-
pearance of symptoms and histology improvement after at
least 12 months of GFD. Furthermore, these ‘seronega-
tive’ patients underwent human leukocyte antigen
(HLA) typing for DQ2 and DQ8 alleles determination
and CD diagnosis was confirmed exclusively in those
carrying these alleles.
CD-specific serum antibody assays and EmA assay in
the culture system
Serum IgA was measured by enzyme-linked immunosor-
bent assay to exclude IgA deficiency. Serum IgA recombi-
nant antihuman tTG antibody and IgA EmA concentrations
were determined with commercial methods as described
previously [11].
A duodenal biopsy specimen was cultured for 72 h at 371C
in the presence of the 31–43 gliadin peptide (0.1
g/l), included in the set, with a commercial kit (EmA-
biopsy, Eurospital, Trieste, Italy), as described pre-
viously [9]. IgA EmA antibodies in undiluted super-
natants were assayed with the same commercial reagent
set used for serum EmA.
Duodenal histology evaluation
At least six forceps biopsy specimens were obtained from
the second duodenal portion during gastroduodenoscopy:
at least four for histology and two for culture. Specimens
adequate in size were immediately oriented and subse-
quently embedded in paraffin. The slides were stained
with hematoxylin and eosin and graded according to the
standardized scheme reported by Oberhuber et al. [10].
All samples collected before the publication of the
Oberhuber’s article had been re-evaluated after the year
1999 and graded according to that report [10] for our
database. In cases with patchy villous atrophy were classi-
fied as grade 3; in cases showing concomitant different
degree of atrophy (3a, 3b, 3c), the most severe grade was
considered. Villous height/crypt depth ratio was measured
and a ratio of less than 2.0 was regarded as Oberhuber’s
grade 3 and compatible with CD. The number of IELs
per 100 villous epithelial cells was assessed by immuno-
histochemical staining: CD3+ IELs were stained with
monoclonal antibody Leu-4. The upper limit of the
reference interval in our laboratory is 25 IELs/100 epi-
thelial cells. In all cases, histology analysis was carried out
by an examiner unaware of the clinical condition and
laboratory test results of the patients.
Human leukocyte antigen testing
Patients with a clinical suspicion of CD but negative
for serum EmA and anti-tTG were typed for HLA-DQ
phenotypes by polymerase chain reaction using
sequence-specific primers. DNA was extracted from
fresh peripheral blood using the standard phenol–
chloroform extraction procedure. Typing was done using
a DR and DQ sequence-specific primers kit (Unipath
SpA, Milan, Italy) or, since March 2006, a rapid method
(DQ-CD Typing Plus by BioDiaGene, Palermo, Italy),
following the recommended procedures [12].
Statistical analysis
The sensitivity and specificity of the methods examined
were calculated by standard statistical methods. Median
and range values were calculated for age and duration of
symptoms. Percentage and the 95% confidence interval
were given for the frequency. The w2-test was used to
compare the sensitivity and the specificity of the serum
and ‘culture medium’ CD antibodies. For this purpose,
serum anti-tTG and serum EmA were considered as a
single test: positivity in one of them was considered
‘positive serology’, negativity in either was ‘negative
serology’.
All the patients, or the children’s parents, included gave
their informed consent and the study was approved by the
Ethics Committee of the University Hospital of Palermo.
Results
A review of the CD records and clinical records showed
that during the study period 1353 patients had undergone
duodenal biopsies for tissue culture and EmA assay in the
culture medium. However, we considered only those
patients who had one follow-up visit at least 1 year after
the first evaluation (median follow-up duration of 8 years,
range: 2–13 years).
In this way, 1123 patients were considered. There were
658 children (302 boys, 356 girls; age range: 1–17 years,
median: 3 years) and 465 adults (171 males, 294 females;
age range: 18–79 years, median: 39 years). All these
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patients had undergone a complete study for suspected
CD, including serum antibodies (EmA and anti-tTG)
assay, duodenal histology study, and HLA study for DQ2
and DQ8 determination.
Clinical characteristics of the study groups
A final diagnosis of CD had been reached in 418 of these
patients: 162 adults (60 males, 102 females; age range:
18–79 years, median: 34 years) and 256 children (106 boys,
150 girls; age range: 1–17 years, median: 4.8 years).
Seven-hundred and five patients had a final diagnosis
other than CD. Among the 303 non-CD adults we had
found one or more of the following diagnoses for each
patient: irritable bowel syndrome in 180 cases, side-
ropenic anemia in 204 cases, peptic ulcer in 51 cases,
lactose intolerance in 30 cases, aphthous stomatitis in 20
cases, multiple food allergy in 37 cases, Crohn’s disease in
10 cases, osteoporosis in 17 cases, chronic hepatitis in
seven cases, autoimmune thyroiditis in 21 cases, dental
enamel defects in nine cases, rheumatoid arthritis in six
cases, Sjogren’s syndrome in four cases, spondiloarthritis
in nine cases, and gynecological disorders in six cases.
Among the 402 non-CD children, we had found one or
more of the following diagnoses for each: cow’s milk
allergy in 151 cases, multiple food allergy in 114 cases,
irritable bowel syndrome in 42 cases, short stature in 41
cases, sideropenic anemia in 87 cases, intestinal giardiasis
in eight cases, aphthous stomatitis in 28 cases, neurologic
symptoms in three cases, liver steatosis with increase in
liver enzyme levels in 18 cases, and type I diabetes
mellitus in seven cases.
Table 1 shows the clinical characteristics of the patients
at diagnosis and Fig. 1 summarizes the study design and
the main results of the study.
Table 2 shows the results of the EmA assay in the culture
medium and in the serum. All patients with CD who were
tested as false-negative for serum EmA and/or anti-tTG
(32 adults and 39 children) carried the HLA alleles
associated to CD, 50 patients showed the DQ2 haplotype
and 21 the DQ8 haplotype.
False-positive results for serum CD antibodies were
found in 15 adults and eight children not suffering from
CD; in 20 of these 23 cases, we found positive-anti-tTG
and negative-EmA assays. All these patients underwent
an accurate follow-up, and serology became negative after
some time (6 months–2 years) while the patients still
were eating gluten.
Two adult patients (female, aged: 32 and 40 years) and
two children were false-positive for EmA in the culture
medium, both adults were suffering from spondiloarthritis
and both children had intestinal giardiasis.
During the study period, 10 ‘culture EmA positive
patients with CD’, all with normal villi architecture
(histology grade: 0–2), had decided against commencing
GFD at the initial evaluation as they did not fulfill the
Table 1 Clinical and serological characteristics of 418 patients with CD and 705 non-CD patients who had undergone EmA assay in the
culture medium of the duodenal biopsy at diagnosis
Adult CD (n=162) Pediatric CD (n=256) Adult non-CD (n=303) Pediatric non-CD (n=402)
Main reason for endoscopy
Abdominal symptoms 97 (60%) 205 (80%) 132 (44%) 282 (70%)
Malabsorption/anemia 49 (30%) 38 (15%) 150 (49%) 104 (26%)
Extraintestinal symptoms 16 (10%) 13 (5%) 21 (7%) 16 (4%)
Family history of CD 32 (20%) 55 (21%) 12 (4%) 20 (5%)
Symptoms duration median (range) 4 years (1–36 years) 7 months (0–36 months) 4.5 years (1–40 years) 6 months (0–39 months)
CD, celiac disease; EmA, antiendomysium.
Fig. 1
Elegible
patients (1353)
(total number of
patients who
underwent EmA
assay)
Studied
patients (1123)
(at least two follow-up visits
after the initial evaluation +
one follow-up visit 1 year after
the first evaluation)
CD
patients (418)
[adults (162)]
[children (256)]
Non-CD
control
patients (705)
[adults (303)]
[children (402)]
Excluded
patients (230)
(lost at the
follow-up)
True-positive culture EmA assay [412 (98.6%)]
Adults (160) vs. 130 positives for serum EmA and/or anti-tTG
Children (252) vs. 217 positives for serum EmA and/or anti-tTG
False-negative culture EmA assay [6 (1.4%)]
Two adults vs. 32 negatives for serum EmA and anti-tTG
Four children vs. 39 negatives for serum EmA and anti-tTG
False-positive culture EmA assay [4 (0.5%)]
Two adults (spondiloarthritis) vs. 15 positives for serum EmA and/or anti-tTG
Two children (giardiasis) vs. eight positives for serum EmA and/or anti-tTG
True-negative culture EmA assay [701 (99.5%)]
Adults (301) vs. 288 negatives for serum EmA and anti-tTG
Children (400) vs. 394 negatives for serum EmA and anti-tTG
Study design and summary of the main results. anti-tTG, antibodies to tissue transglutaminase; CD, celiac disease; EmA, antiendomysium.
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CD diagnostic criteria. However, on a gluten-containing
diet, they had continued to suffer from various troubles
and all had undergone yearly further serologic and
histology evaluations. Four of them had become positive
for serum EmA-anti-tTG in a median time of 3 years
(range: 1–5 years) and at that time intestinal histology
had shown villous atrophy in all cases (grade 3A–3B)
(Fig. 2), and they had commenced a GFD.
The other six patients remained negative for serum CD
antibodies but at subsequent intestinal evaluations had
shown persistent positivity for EmA in the culture
medium, although histology severity was unchanged
(histology grade: 0–2). However, these six patients also
decided to adhere to a strict GFD (a median time of 3.5
years after the first evaluation, range: 1–6 years), as their
symptoms had worsened with time.
Seven of these 10 patients carried the HLA DQ2
genotype whereas the remaining three patients carried
the HLA DQ8 genotype. On GFD, all became asympto-
matic without anemia or other signs of malabsorption.
Intestinal histology re-evaluated after commencing GFD
Table 2 Results of the EmA assay in the culture medium and in the
sera of the adult and pediatric patients. Sensitivity and specificity
values (c.i.) in CD diagnosis are also indicated
Adults CD Patients (n. 162) Non-CD Patients (n. 303)
Positive EmA in culture 160 (99%) 2 (0.5%)
Negative EmA in culture 2 (1%) 301 (99.5%)
Sensitivity 99% (97–100)a —
Specificity 99.5% (98.4–100)b —
Positive serum EmA 130 (80%) 15 (5%)
Negative serum EmA 32 (20%) 288 (95%)
Sensitivity 80% (78.1–83)a —
Specificity 95% (92.6–97.5)b —
Children CD Patients (n. 256) Non-CD Patients (n. 404)
Positive EmA in culture 252 (98.4%) 2 (0.5%)
Negative EmA in culture 4 (1.5%) 402 (99.5%)
Sensitivity 98.4% (96–99)c —
Specificity 99.5% (98–100) —
Positive serum EmA 217 (85%) 8 (2%)
Negative serum EmA 39 (15%) 394 (98%)
Sensitivity 85% (80.4–89.1)c —
Specificity 98% (96.6–99.3) —
Statistical analysis
aw2= 27.6 P<0.0001 (sensitivity in adults).
bw2 =8.7 P=0.004 (specificity in adults).
cw2= 29.3 P=0.0001 (sensitivity in children).
Fig. 2
MARSH-1 H-E
(a)
(c)
(b) MARSH-1 CD3
MARSH-3c H-E
Histology pictures of one of the patients with positive-antiendomysium (EmA) in the culture medium and negative-serum EmA, at first evaluation [(a)
hematoxylin and eosin, 40" ; (b) anti-CD3 staining], an infiltrative pattern without villous atrophy is shown. The duodenal histology of the same
patient after 2 years, at the time of re-evaluation, when serum EmA became positive [(c) hematoxylin and eosin, 40" ], intestinal villous atrophy is now
evident.
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(after a median time of 1.5 years, range: 14–24 months)
showed a consistent improvement, that is, all had normal
or inflamed mucosa (grade 0–1 of Oberhuber’s classifica-
tion) without villous atrophy (Table 3). At this time, EmA
assay in the culture medium resulted in being negative in
seven out of the 10 patients.
Discussion
The growing contribution of serology to CD diagnosis has
been recently underlined by Kurppa et al. [7,13]. both in
adults and in children. These investigators concluded
that the diagnostic criteria for CD need to be re-
evaluated and that EmA positivity without atrophy
warrants dietary treatment. Other studies have shown
that gluten sensitivity and malabsorption may coexist
with a normal-looking mucosa [2–4].
However, positive-serum antibodies have been shown to
correlate with degree of villous atrophy, and patients with
CD with less severe histological damage can be
seronegative for CD [14–16]. Thus, it is highly likely
that symptomatic patients with CD with minimal
histology lesions and negative-serology remain undiag-
nosed. Obviously, the actual size of this patient group is
unknown but the prevalence of gluten sensitivity in an
architecturally normal small bowel is known to be
increasing [17,18]. In contrast, it is now well-known that
villous atrophy could be detected only in duodenal
bulb [19] and this could determine a bias in the studies,
including the present, in which the duodenal biopsies
were performed in the second part of the duodenum.
Our study poses its basis on the evidence that EmA anti-
bodies are produced in the intestinal mucosa [20], and
recently Stenman et al. [21] showed that secretion of CD
autoantibodies after in-vitro gliadin challenge is depen-
dent on small-bowel mucosal transglutaminase 2-specific
IgA deposits. Furthermore, recent findings suggest that
these TG2-targeted mucosal IgA-autoantibody deposits
are already present in the early phases of the disease
before autoantibodies appear in the serum [22,23].
This evaluation of more than 1000 patients referred to
our centers for suspected CD confirmed that EmA assay
in a simple culture system has a significantly higher
sensitivity than serum anti-tTG/EmA assays. Although we
must underline the limitation that our data were derived
from a retrospective study, we included the most
numerous group of patients considered in studies
evaluating the diagnostic accuracy of the antibodies
assays in CD diagnosis. We showed that, both in adults
and in children, EmA in a culture medium had a
sensitivity of 99%, compared with 80–85% in the serum.
The sensitivity of serum anti-tTG and EmA, which we
found in our study, could be considered low, but we agree
with the opinion of Catassi and Fasano who affirmed that
‘Seronegative CD is likely to be underestimated due to
the tendency to perform small-intestinal biopsy only in
patients with positive-CD serum markers (so-called self-
fulfilling prophecy)’ [24].
It is very interesting that in a small group of patients (first
four of Table 3), the comparison of the histology pictures at
the first evaluation, when EmAs were positive in the cul-
ture medium but not in the serum, and subsequently when
EmAs became positive also in the serum, showed a progres-
sion in severity of the lesions, from a ‘simple inflammation’
to villous atrophy. This progression has also been shown in
studies [21,22], which demonstrated anti-TG antibody
deposits in the small-bowel mucosa even when absent in
the serum. On the basis of those studies, it has been sug-
gested that the immunohistochemistry demonstration of
anti-tTG deposits can be used in the diagnosis of serone-
gative CD, when histology is equivocal. Similarly, we would
suggest that EmAs positivity in the culture medium of the
biopsy could be used in the CD diagnosis of seronegative
patients. Obviously, a prospective study including a consis-
tent number of these patients needs to further confirm the
usefulness of EmA assay in the culture medium.
In an era in which intestinal histology evaluation can no
longer be considered, the corner stone of CD diagnosis
and ‘microscopic enteritis’ has been included in the
Table 3 Clinical and histological characteristics of 10 patients negative for serum anti-tTG/EmA and without evidence of intestinal villi
atrophy, but positive for EmA in the culture medium of the intestinal biopsies, at the time of the first evaluationa
Histology
at the first
evaluation
Histology at
the time of the
decision of
commencing GFD
Histology after
14–24 months
of GFD diet
Hb values at the
first evaluation
(g/dl)
Hb values after
14–24 months
of GFD diet
(g/dl)
Abdominal
pain/diarrhea
at the first
evaluation
Abdominal
pain/diarrhea after
14–24 months
of GFD diet
Male, age=19 years Grade 1 Grade 3A Grade 0 10 12.6 Yes/No No/No
Female, age=32 years Grade 1 Grade 3B Grade 1 10.8 13.0 Yes/Yes No/No
Female, age=26 years Grade 0 Grade 3B Grade 0 12.2 12.8 Yes/Yes No/No
Female, age=56 years Grade 1 Grade 3A Grade 1 11.1 13.1 Yes/Yes No/No
Female, age=26 years Grade 1 Grade 1 Grade 1 8.9 12.0 Yes/Yes No/No
Female, age=27 years Grade 0 Grade 1 Grade 0 13.1 12.3 Yes/Yes No/No
Male age=36 years Grade 1 Grade 1 9.9 12.4 Not/Yes Not/Not
Female, age=3 years Grade 2 Grade 1 10.8 12.8 Yes/Yes Not/Not
Male age=6 years Grade 1 Grade 0 11 12.7 Yes/Not Not/Not
Female, age=2 years Grade 0 Grade 1 12.1 13.5 Yes/Not Not/Not
EmA, antiendomysium; GFD, gluten-free diet
aA comparison between gluten-containing diet period and GFD period is shown.
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possible pictures of patients with CD [25], clinicians
need to evaluate symptoms, serology, histology, genetics
and, eventually, respond to GFD. This diagnostic puzzle
is, however, very difficult to piece together in an
increasing number of cases.
The data of this study indicated that no more than one
biopsy for the culture system and EmA assay in the
medium culture increased the sensitivity and specificity
of CD diagnosis, revealing a number of patients with CD
who could have remained undiagnosed, and avoiding a
number of ‘probable CD’ diagnoses which would have
been proved to be wrong over time.
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